Fundraising Fox
OssiFi
Overland Park, US · Delaware corporation
Find your way into OssiFi
Sign up to see every warm intro you have to OssiFi
- Paths you didn't know you had: your email and LinkedIn already hold routes to the OssiFi team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
OssiFi develops small molecule therapeutics targeting bone growth modulation, specifically focusing on inhibiting Wnt pathway regulators to treat conditions like osteoporosis. The company leverages established drug development technologies and manufacturing expertise to advance candidates through clinical development.
Founders & leadership
DL
Debra L ElliesChief Executive OfficerDebra L Ellies is Executive Officer at OssiFi, where she has led bone regenerative medicine research for over 18 years, including work on sclerostin-blocking therapeutics. She holds expertise in molecular embryology and anatomy, serves as a trustee at MRIGlobal, and has contributed to the development of therapies targeting bone-related conditions.
Board
FL
Frank LoefflerBoard director
KD
Kelly DrouillardBoard director
Reported raises · per SEC filings
Form D private placements$2M disclosed across 3 rounds · 2016–2018
▶$1.5MraisedNov 2018 · 17 investors · PharmaceuticalsRule 506(b)
▶$1.5MraisedNov 2018 · 17 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Debra L ElliesExecutive Officer
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- Minimum investment
- $50K
- Proceeds to insiders
- $90K
- First sale
- Oct 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 04, 06b, 4a5
▶$361KraisedApr 2017 · 15 investors · PharmaceuticalsRule 506(b)
▶$361KraisedApr 2017 · 15 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Debra L ElliesExecutive Officer, Director
- Kelly DrouillardDirector
- Frank LoefflerDirector
- Amount sold
- $361K
- Minimum investment
- $50K
- Proceeds to insiders
- $64.6K
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 04, 06b, 4a5
▶$96.4KraisedSep 2016 · 4 investors · PharmaceuticalsRule 506(b)
▶$96.4KraisedSep 2016 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Frank LoefflerDirector
- Kelly DrouillardDirector
- Debra L ElliesExecutive Officer
- Offering amount
- $400K
- Amount sold
- $96.4K
- Minimum investment
- $50K
- Proceeds to insiders
- $60K
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 04, 06b, 4a5
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as OssiFi.
Frequently asked questions
- What does OssiFi do?
- OssiFi develops small molecule therapeutics targeting bone growth modulation, specifically focusing on inhibiting Wnt pathway regulators to treat conditions like osteoporosis. The company leverages established drug development technologies and manufacturing expertise to advance candidates through clinical development.
- How much funding has OssiFi raised?
- OssiFi has disclosed $2M raised across 3 rounds.
- Where is OssiFi headquartered?
- OssiFi is headquartered in Overland Park, US.